Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2021-09-14 4:30 pm Unchanged | 13D | POINT Biopharma Global Inc. PNT | RA CAPITAL MANAGEMENT L.P. | 8,856,018 9.8% | 0 (Unchanged) | View |
| 2021-07-20 4:31 pm Purchase | 13G | POINT Biopharma Global Inc. PNT | RA CAPITAL MANAGEMENT L.P. | 8,856,018 9.8% | 8,856,018 (New Position) | View |
| 2021-07-12 4:37 pm Purchase | 13D | POINT Biopharma Global Inc. PNT | SILBER ALLAN C | 8,865,788 9.8% | 8,865,788 (New Position) | View |
| 2021-06-30 4:32 pm Purchase | 13D | POINT Biopharma Global Inc. PNT | RA CAPITAL MANAGEMENT L.P. | 1,098,318 7.8% | 1,098,318 (New Position) | View |
| 2021-05-10 4:08 pm Purchase | 13G | POINT Biopharma Global Inc. PNT | RIVERVIEW GROUP LLC | 940,000 6.7% | 940,000 (New Position) | View |
| 2021-04-02 10:59 am Purchase | 13G | POINT Biopharma Global Inc. PNT | SUVRETTA CAPITAL MANAGEMENT LLC | 1,095,400 7.8% | 1,095,400 (New Position) | View |
| 2021-02-16 3:45 pm Purchase | 13G | POINT Biopharma Global Inc. PNT | PERCEPTIVE ADVISORS LLC | 1,500,000 10.7% | 1,500,000 (New Position) | View |
| 2021-02-16 12:24 pm Purchase | 13G | POINT Biopharma Global Inc. PNT | PRICE T ROWE ASSOCIATES INC | 921,822 5.2% | 921,822 (New Position) | View |
| 2021-02-12 7:58 pm Sale | 13G | POINT Biopharma Global Inc. PNT | BIOTECHNOLOGY VALUE FUND L P | 954,996 6.8% | -45,004 (-4.50%) | View |
| 2021-02-12 08:10 am Purchase | 13G | POINT Biopharma Global Inc. PNT | Avoro Capital Advisors LLC | 1,000,000 7.1% | 1,000,000 (New Position) | View |
| 2021-02-05 5:51 pm Unchanged | 13G | POINT Biopharma Global Inc. PNT | BlackRock Inc. BLK | 1,500,000 10.7% | 0 (Unchanged) | View |
| 2021-02-04 10:27 am Purchase | 13G | POINT Biopharma Global Inc. PNT | WELLINGTON MANAGEMENT GROUP LLP | 877,832 6.25% | 877,832 (New Position) | View |
| 2021-02-02 3:13 pm Purchase | 13G | POINT Biopharma Global Inc. PNT | FRANKLIN RESOURCES INC BEN | 1,000,000 7.1% | 1,000,000 (New Position) | View |
| 2020-09-09 3:52 pm Purchase | 13G | POINT Biopharma Global Inc. PNT | BlackRock Inc. BLK | 1,500,000 10.7% | 1,500,000 (New Position) | View |
| 2020-07-20 4:37 pm Purchase | 13G | POINT Biopharma Global Inc. PNT | Boxer Capital LLC | 1,500,000 8.8% | 1,500,000 (New Position) | View |
| 2020-07-20 4:35 pm Purchase | 13G | POINT Biopharma Global Inc. PNT | BIOTECHNOLOGY VALUE FUND L P | 1,000,000 5.9% | 1,000,000 (New Position) | View |
| 2020-07-20 4:16 pm Purchase | 13G | POINT Biopharma Global Inc. PNT | Bain Capital Life Sciences Fund II L.P. | 891,429 6.3% | 891,429 (New Position) | View |